Health Stocks in Motion
Updated from 3:28 p.m. EDT
Shares of Alpharma (ALO) were among the best-performing health-related stocks Friday, rising 7.8% after the company posted first-quarter earnings that were ahead of expectations.
Excluding items, the generic drugmaker posted earnings of $19.3 million, or 37 cents a share, on sales of $378.1 million. Analysts polled by Thomson First Call were expecting earnings of 28 cents a share on sales of $378.2 million. A year ago the company earned $2.5 million, or 5 cents a share, on sales of $311.7 million. The strong year-over-year sales gains were attributed to higher generic pharmaceuticals business, which benefited from the launches of gabapentin capsules and tablets during the fourth quarter of 2004.
Despite the upbeat gabapentin sales news, the company said its U.S. generics business continues to face significant challenges. Looking ahead, Alpharma reiterated its 2005 earnings outlook, saying that it continues to believe 2005 results will not exceed 2004 levels. Results for 2005 will be affected by continued weakness in the company's U.S. generics business, it said, and by an absence of a benefit for U.S. tax losses in the consolidated tax provision. Shares traded up 79 cents to $10.89.Harvard Bioscience (HBIO) fell 9.3% after the company posted first-quarter results that fell below expectations. The company posted adjusted earnings of $806,000, or 3 cents a share, on sales of $22.4 million. Analysts were expecting earnings of 5 cents a share on sales of $23.4 million. A year ago the company earned $798,000, or 3 cents a share, on sales of $22.2 million. Despite the first-quarter shortfall, the company backed its 2005 earnings and sales guidance. In March the company said that it would post adjusted 2005 earnings of 22 cents to 26 cents a share on sales of $95 million to $100 million. Analysts are expecting earnings of 24 cents a share on sales of $99 million. Shares traded down 36 cents to $3.52.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV